Literature DB >> 11556200

[Radioiodine therapy of Graves' disease--a dosimetric comparison of various therapy regimens of antithyroid agents].

V Urbannek1, E Voth, D Moka, H Schicha.   

Abstract

AIM: Premedication with antithyroid drugs (ATD) compared to patients not pretreated with ATD causes a higher failure rate of radioiodine therapy (RITh) or demands higher therapeutical dosage of radioiodine (RI). For clinical reasons and because of accelerated iodine metabolism in hyperthyreosis a compensated thyroid metabolism is desirable. Aim of this study was to investigate the influence of ATD on the biokinetics of RI in case of Graves' disease in order to improve RITh of patients pre-treated with ATD.
METHODS: 385 consecutive patients who underwent RITh because of Graves' disease for the first time were included: Group A (n = 74): RITh under continuous medication with ATD; Group B (n = 111): Application of RI under continuous medication with ATD, in case of insufficient RI-uptake or shortened effective RI-half-life ATD were stopped 1-5 days after RITh; Group C (n = 200): ATD were stopped 2 days prior to RITh in all patients. We examined the influence of ATD on RI-uptake and effective RI-half-life as well as the absorbed dose achieved on the thyroid in dependence of thyroid volume and applied RI-dosage [TEQ--therapy efficiency quotient, (2)].
RESULTS: In the RI-pretest (all patients under ATD) the RI-uptake was comparable in all three groups. During RITh RI-uptake, effective RI-half-life and therefore the TEQ were significantly higher in Group C as compared to Groups A and B (p < 0.001, respectively). In Group B the medication with ATD was stopped in 61 of 111 cases 1-5 days after RITh. In this subgroup the effective RI-half-life increased from 4.4 +/- 1.7 d to 5.1 +/- 1.6 d after stopping of ATD (p = 0.001).
CONCLUSION: Stopping of ATD 2 days prior to RITh leads to an increased efficiency of about 50% compared to RITh carried out under ATD and therefore to a clear reduction of radiation exposure to the rest of the body with equal absorbed doses of the thyroid. Stopping of ATD shortly after RITh increases efficiency in case of short effective RI-half-life, but it is inferior to stopping ATD 2 days prior to RITh.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11556200

Source DB:  PubMed          Journal:  Nuklearmedizin        ISSN: 0029-5566            Impact factor:   1.379


  6 in total

1.  Influence of antithyroid drugs on the outcome of radioiodine therapy in Graves' disease and toxic nodular goitre.

Authors:  O Sabri; M Zimny; U Buell
Journal:  Eur J Nucl Med Mol Imaging       Date:  2001-11-09       Impact factor: 9.236

2.  Change in the intrathyroidal kinetics of radioiodine under continued and discontinued antithyroid medication in Graves' disease.

Authors:  Simone Dunkelmann; Hubertus Kuenstner; Elham Nabavi; Bettina Rohde; Peter Groth; Carl Schuemichen
Journal:  Eur J Nucl Med Mol Imaging       Date:  2006-09-22       Impact factor: 9.236

3.  Investigation of factors influencing radioiodine (131I) biokinetics in patients with benign thyroid disease using nonlinear mixed effects approach.

Authors:  Valentina Topić Vučenović; Zvezdana Rajkovača; Dijana Jelić; Dragi Stanimirović; Goran Vuleta; Branislava Miljković; Katarina Vučićević
Journal:  Eur J Clin Pharmacol       Date:  2018-05-13       Impact factor: 2.953

4.  Analysis of demographic and clinical factors affecting the outcome of radioiodine therapy in patients with hyperthyroidism.

Authors:  Małgorzata Knapska-Kucharska; Lidia Oszukowska; Andrzej Lewiński
Journal:  Arch Med Sci       Date:  2010-09-07       Impact factor: 3.318

5.  Effects of drugs on the efficacy of radioiodine (|) therapy in hyperthyroid patients.

Authors:  Lidia Oszukowska; Małgorzata Knapska-Kucharska; Andrzej Lewiński
Journal:  Arch Med Sci       Date:  2010-03-09       Impact factor: 3.318

6.  Effectiveness of Radioiodine Treatment for Toxic Nodular Goiter.

Authors:  Hatice Şakı; Arzu Cengiz; Yakup Yürekli
Journal:  Mol Imaging Radionucl Ther       Date:  2015-10-05
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.